Nonalcoholic fatty liver disease and vascular risk

Current Opinion in Cardiology

Volumn 27, Issue 4, 2012, Pages 420-428

  Bhatia, Lokpal S ^a,b,c   Curzen, Nicholas P ^a,b   Byrne, Christopher D ^a,c  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

cardiovascular disease; ectopic fat; insulin resistance; nonalcoholic fatty liver disease; risk factor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; OMEGA 3 ACID ETHYL ESTER; PIOGLITAZONE; POLYUNSATURATED FATTY ACID; RIMONABANT; ROSIGLITAZONE; TELMISARTAN; TETRAHYDROLIPSTATIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BARIATRIC SURGERY; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CASE CONTROL STUDY; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SAMPLING;

CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FATTY LIVER; HUMANS; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; RISK FACTORS;

EID: 84862300888     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328354829c     Document Type: Review

References (73)

1. Musso G, Gambino R, Cassader M, Pagano G. Meta-Analysis: Natural history of nonalcoholic fatty liver disease (NAFLD) and diagnostic accuracy of noninvasive tests for liver disease severity. Ann Med 2011; 43:617-649.
2. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004; 40:1387-1395.
3. Wong VW, Chu WC, Wong GL, et al. Prevalence of nonalcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: A population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012; 61:409-415.
4. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53:372-384.
5. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34:274-285.
6. Wong VW, Wong GL, Choi PC, et al. Disease progression of nonalcoholic fatty liver disease: A prospective study with paired liver biopsies at 3 years. Gut 2010; 59:969-974.
7. Anstee QM, McPherson S, Day CP. How big a problem is nonalcoholic fatty liver disease? BMJ 2011; 343:d3897.
8. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37:917-923.
9. Drapkina OM, Ivashkin VT. Risk factors for nonalcoholic fatty liver disease in Russian Federation in national-wide direg-l-01903 study. Endocr Prac 2011; 17:14A-15A.
10. Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51:595-602.
11. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Nonalcoholic fatty liver disease: A new and important cardiovascular risk factor? Eur Heart J 2012. doi: 10.1093/eurheartj/ehr453. [Epub ahead of print]
12. Schwenzer NF, Springer F, Schraml C, et al. Noninvasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51:433-445.
13. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: The diagnosis and staging of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2011; 33:525-540.
14. Anty R, Iannelli A, Patouraux S, et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of nonalcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 2010; 32:1315-1322.
15. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363:1341-1350.
16. Fraser A, Harris R, Sattar N, et al. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: Analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 2007; 27:2729-2735.
17. Calori G, Lattuada G, Ragogna F, et al. Fatty liver index and mortality: The Cremona study in the 15th year of follow-up. Hepatology 2011; 54:145-152.
18. Lazo M, Hernaez R, Bonekamp S, et al. Nonalcoholic fatty liver disease and mortality among US adults: Prospective cohort study. BMJ 2011; 343:d6891.
19. Gova E, Sianni A, Feretou C, et al. Non alcoholic fatty liver disease (NAFLD) is a major risk factor for cardiovascular disease in patients with type 2 diabetes mellitus. Diabetologia 2011; 54:S109.
20. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 2010; 53:713-718.
21. Hudson S, Bhatia L, McCormick KG, et al. Nonalcoholic fatty liver disease severity is related to increased cardiovascular risk independently of hyperglycaemia and obesity. Diabetologia 2011; 54:S110.
22. Treeprasertsuk S, Leverage S, Adams LA, et al. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 2012. doi: 10.1111/j.1478-3231. [Epub ahead of print]
23. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk: A systematic review and meta-Analysis. J Am Coll Cardiol 2010; 56:1113-1132.
24. Lucero D, Zago V, Lopez GI, et al. Pro-inflammatory and atherogenic circulating factors in nonalcoholic fatty liver disease associated to metabolic syndrome. Clinica Chimica Acta 2011; 412:143-147.
25. Targher G, Bertolini L, Rodella S, et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008; 16:1394-1399.
26. Chiang C-H, Huang C-C, Chan WL, et al. The severity of nonalcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population. Clin Biochem 2010; 43:1399-1404.
27. Abdulla J, Asferg C, Kofoed KF. Prognostic value of absence or presence of coronary artery disease determined by 64-slice computed tomography coronary angiography: A systematic review and meta-Analysis. Int J Cardiovasc Imaging 2011; 27:413-420.
28. Kim D, Choi SY, Park EH, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012. doi:10.1002/hep.25593. [Epub ahead of print]
29. Kang MK, Yoon H, Seon H, et al. Association between nonalcoholic fatty liver disease and subclinical coronary atherosclerosis determined by mdct. Hepatology 2011; 54:1115A-1116A.
30. Wong VW, Wong GL, Yip GW, et al. Coronary artery disease and cardiovascular outcomes in patients with nonalcoholic fatty liver disease. Gut 2011; 60:1721-1727.
31. Sun L, Lu SZ. Association between nonalcoholic fatty liver disease and coronary artery disease severity. Chin Med J (Engl) 2011; 124:867-872.
32. Polak JF, Pencina MJ, Pencina KM, et al. Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med 2011; 365:213-221.
33. Sookoian S, Pirola CJ. Nonalcoholic fatty liver disease is strongly associated with carotid atherosclerosis: A systematic review. J Hepatol 2008; 49:600-607.
34. Kozakova M, Palombo C, Paterni M, et al. Fatty liver index, gamma-glutamyltransferase and early carotid plaques. Hepatology 2012; 55:1406-1415.
35. Mohammadi A, Bazazi A, Ghasemi-Rad M. Evaluation of atherosclerotic findings in patients with nonalcoholic fatty liver disease. Int J Gen Med 2011; 4:717-722.
36. Ying I, Saposnik G, Vermeulen MJ, et al. Nonalcoholic fatty liver disease and acute ischemic stroke. Epidemiology 2011; 22:129-130.
37. Targher G, Chonchol M, Zoppini G, et al. Risk of chronic kidney disease in patients with nonalcoholic fatty liver disease: Is there a link? J Hepatol 2011; 54:1020-1029.
38. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
39. Arase Y, Suzuki F, Kobayashi M, et al. The development of chronic kidney disease in Japanese patients with nonalcoholic fatty liver disease. Intern Med 2011; 50:1081-1087.
40. Yasui K, Sumida Y, Mori Y, et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism 2011; 60:735-739.
41. Machado MV, Goncalves S, Carepa F, et al. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int 2012; 32:241-248.
42. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia and nonalcoholic fatty liver disease (NAFLD): A relationship with implications for vascular risk? Curr Vasc Pharmacol 2011; 9:698-705.
43. Seo JM, Park TH, Lee DY, et al. Subclinical myocardial dysfunction in metabolic syndrome patients without hypertension. J Cardiovasc Ultrasound 2011; 19:134-139.
44. Dinh W, Lankisch M, Nickl W, et al. Metabolic syndrome with or without diabetes contributes to left ventricular diastolic dysfunction. Acta Cardiol 2011; 66:167-174.
45. Wong CK, Burgess MI, Irwin A, et al. Evidence of diastolic dysfunction in NAFLD: A study using tissue Doppler echocardiography. Diabetologia 2010; 53:S495-S496.
46. Wong CKL, Burgess MI, Pugh CJ, et al. Elevated liver fat in non alcoholic fatty liver disease is associated with impaired myocardial relaxation. J Diabetes 2011; 3:S202.
47. Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 2008; 51:93-102.
48. Vlachopoulos C, Manesis E, Baou K, et al. Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: A pilot study. Am J Hypertens 2010; 23:1183-1189.
49. Sciacqua A, Perticone M, Miceli S, et al. Endothelial dysfunction and nonalcoholic liver steatosis in hypertensive patients. Nutr Metab Cardiovasc Dis 2011; 21:485-491.
50. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353:999-1007.
51. Chiang CH, Huang PH, Chung FP, et al. Decreased circulating endothelial progenitor cell levels and function in patients with nonalcoholic fatty liver disease. PLoS One 2012; 7:e31799.
52. Shin W-Y, Jung D-H, Shim J-Y, Lee H-R. The association between nonalcoholic hepatic steatosis and mean platelet volume in an obese Korean population. Platelets 2011; 22:442-446.
53. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest 2006; 116:1813-1822.
54. Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008; 134:1369-1375.
55. Rijzewijk LJ, Jonker JT, Van Der Meer RW, et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J Am Coll Cardiol 2010; 56:225-233.
56. Watts GF, Karpe F. Triglycerides and atherogenic dyslipidaemia: Axtending treatment beyond statins in the high-risk cardiovascular patient. Heart 2011; 97:350-356.
57. Targher G, Chonchol M, Miele L, et al. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009; 35:277-287.
58. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50:957-969.
59. Barseghian A, Gawande D, Bajaj M. Adiponectin and vulnerable atherosclerotic plaques. J Am Coll Cardiol 2011; 57:761-770.
60. Amaro A, Fabbrini E, Kars M, et al. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 2010; 139:149-153.
61. Stanton MC, Chen SC, Jackson JV, et al. Inflammatory signals shift from adipose to liver during high fat feeding and influence the development of steatohepatitis in mice. J Inflamm (London) 2011; 8:8.
62. Tarantino G, Caputi A. JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease. World J Gastroenterol 2011; 17:3785-3794.
63. Gastaldelli A, Basta G. Ectopic fat and cardiovascular disease: What is the link? Nutr Metab Cardiovasc Dis 2010; 20:481-490.
64. Lai YH, Yun CH, Yang FS, et al. Epicardial adipose tissue relating to anthropometrics, metabolic derangements and fatty liver disease independently contributes to serum high-sensitivity C-reactive protein beyond body fat composition: A study validated with computed tomography. J Am Soc Echocardiogr 2012; 25:234-241.
65. Xu Y, Cheng X, Hong K, et al. How to interpret epicardial adipose tissue as a cause of coronary artery disease: A meta-Analysis. Coron Artery Dis 2012. doi:10.1097/MCA. [Epub ahead of print]
66. Musso G, Gambino R, Cassader M, Pagano G. A meta-Analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52:79-104.
67. Marchesini G, Moscatiello S, Agostini F, et al. Treatment of nonalcoholic fatty liver disease with focus on emerging drugs. Expert Opin Emerg Drugs 2011; 16:121-136.
68. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on nonalcoholic fatty liver disease in metabolic syndrome: A randomised study. Curr Med Res Opin 2006; 22:873-883.
69. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97:77C-81C.
70. Bader T. Liver tests are irrelevant when prescribing statins. Lancet 2010; 376:1882-1883.
71. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A posthoc analysis. Lancet 2010; 376:1916-1922.
72. Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: A post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011; 7:796-805.
73. Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54:344-353.